Biosketch

Prof. dr. Gert Moll

Gert Moll has a solid background in microbiology (PhD in 1990) and has worked on Plasmodium-infected red blood cells (INSERM/CNRS Montpellier), Helicobacter pylori (Università di Padova), lactic acid bacteria, lanthipeptide genetics (biosynthesis engineering), and cell biology (INSERM Paris). His experience in pharmacology was initiated as Co-Founder, CSO and CEO of the start-up company Lanthio Pharma B.V. that won the Gouden Kiem Award as Best Dutch Startup Company of the Year in 2014 and that was acquired by MorphoSys AG. His main current interests include:

• Bacterial and viral genetics

• Biosynthesis and engineering of RiPPs

• Bacterial and phage display of lanthipeptides

• Lanthionine-constrained GPCR-agonists

• (Pre)clinical development of antibiotics and lanthipeptide hormones

Much of his recent work has medical relevance as witnessed by publications on therapeutic efficacy of lanthipeptide-GPCR agonists in disease models of serious diseases such as diabetes type 1 and diabetes type 2, myocardial infarct, cerebral stroke, acute lung injury, acute respiratory distress syndrome, thrombocytopenia, and colorectal carcinoma. Gert has been involved in a successful phase Ia clinical trial of lanthipeptide LP2, which showed excellent safety and excellent pharmacokinetics.